Quest Diagnostics Inc  

(Public, NYSE:DGX)   Watch this stock  
Find more results for DGX
+0.52 (0.85%)
Real-time:   11:07AM EST
NYSE real-time data - Disclaimer
Currency in USD
Range 61.55 - 62.34
52 week 59.65 - 89.00
Open 61.75
Vol / Avg. 148,757.00/1.15M
Mkt cap 8.74B
P/E 12.67
Div/yield 0.40/2.59
EPS 4.88
Shares 143.00M
Beta 0.66
Inst. own 94%
Apr 21, 2016
Q1 2016 Quest Diagnostics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jan 28, 2016
Q4 2015 Quest Diagnostics Inc Earnings Release
Jan 28, 2016
Q4 2015 Quest Diagnostics Inc Earnings Call - Webcast
Jan 12, 2016
Quest Diagnostics Inc at JPMorgan Healthcare Conference - Webcast
Dec 2, 2015
Quest Diagnostics Inc at Evercore ISI Medtools & Outsourcing Investor Forum
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 10.82% 10.05%
Operating margin 12.93% 18.67%
EBITD margin - 19.67%
Return on average assets 8.01% 7.60%
Return on average equity 16.26% 15.78%
Employees 45,000 -
CDP Score - 83 C


3 Giralda Farms
United States - Map
+1-973-5202700 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business, consists of two parts, develops and delivers diagnostic testing, information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, patients and other customers. Diagnostics Information Services business also provides diagnostic information services, which includes providing clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Company’s other businesses, including central laboratory testing for pharmaceutical and medical device clinical trials, risk assessment services, diagnostic products and healthcare information technology.

Officers and directors

Stephen H. Rusckowski President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Mark J. Guinan Chief Financial Officer, Senior Vice President
Age: 53
Bio & Compensation  - Reuters
Michael E. Prevoznik Senior Vice President, General Counsel
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jon Roger Cohen M.D. Senior Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Everett V. Cunningham Senior Vice President - Commercial
Age: 48
Bio & Compensation  - Reuters
James E. Davis Senior Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
Catherine T. Doherty Senior Vice President - Clinical Franchises
Age: 52
Bio & Compensation  - Reuters
Daniel C. Stanzione Ph.D. Non-Executive Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
John C. Baldwin M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Jenne K. Britell Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters